ES2162040T3 - Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios. - Google Patents

Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios.

Info

Publication number
ES2162040T3
ES2162040T3 ES96909041T ES96909041T ES2162040T3 ES 2162040 T3 ES2162040 T3 ES 2162040T3 ES 96909041 T ES96909041 T ES 96909041T ES 96909041 T ES96909041 T ES 96909041T ES 2162040 T3 ES2162040 T3 ES 2162040T3
Authority
ES
Spain
Prior art keywords
conjugate
citostatic
inflammatory drugs
produce anti
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909041T
Other languages
English (en)
Inventor
Hannsjorg Sinn
Hans-Herrmann Schrenk
Wolfgang Maier-Borst
Gerd Stehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Application granted granted Critical
Publication of ES2162040T3 publication Critical patent/ES2162040T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE AL USO DE UN CONJUGADO DE UNA SUSTANCIA ACTIVA Y UNA PROTEINA NATIVA NO CONSIDERADA COMO EXTRAÑA POR EL ORGANISMO, PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO Y/O DIAGNOSTICO DE ENFERMEDADES INFLAMATORIAS, INFECCIOSAS Y/O DE LA PIEL.
ES96909041T 1995-04-13 1996-04-12 Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios. Expired - Lifetime ES2162040T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19514088A DE19514088A1 (de) 1995-04-13 1995-04-13 Konjugat zur Behandlung von Entzünduns-, Infektions- und/oder Hauterkrankungen

Publications (1)

Publication Number Publication Date
ES2162040T3 true ES2162040T3 (es) 2001-12-16

Family

ID=7759679

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909041T Expired - Lifetime ES2162040T3 (es) 1995-04-13 1996-04-12 Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios.

Country Status (8)

Country Link
US (1) US6706713B1 (es)
EP (1) EP0820308B1 (es)
JP (1) JPH11503433A (es)
AT (1) ATE203680T1 (es)
DE (2) DE19514088A1 (es)
DK (1) DK0820308T3 (es)
ES (1) ES2162040T3 (es)
WO (1) WO1996032133A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19847362A1 (de) * 1998-10-14 2000-04-20 Deutsches Krebsforsch Makromolekulare Wirkstoffkonjugate und Verfahren zu ihrer Herstellung
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
DE102017204850A1 (de) 2017-03-22 2018-09-27 Michael Denck HSA-Konjugat

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179959A1 (en) * 1982-04-20 1986-05-07 Merck Frosst Canada Inc. Conjugates of leukotrienes with proteins
US4767745A (en) * 1982-04-20 1988-08-30 Merck Frosst Canada, Inc. Conjugates of leukotrienes with proteins
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
WO1987004351A1 (en) * 1986-01-16 1987-07-30 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5051406A (en) * 1987-03-04 1991-09-24 Nippon Hypox Laboratories Incorporated Pharmaceutical composition using albumin as a carrier and process for producing the same
NO881077L (no) 1987-03-11 1988-09-12 Univ Michigan Kjemo-radio-immuno-konjugater.
JPS63267734A (ja) * 1987-04-25 1988-11-04 Hiroshi Maeda 腫瘍および炎症用診断薬
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
IT8922275A0 (it) * 1990-10-25 1989-11-06 Baldacci Lab Spa Nuovi derivati di corticosteroidi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
CA2113837A1 (en) * 1991-08-02 1993-02-18 Kenji Mizumoto Anti-hiv agent
JPH07506830A (ja) * 1992-05-15 1995-07-27 マリンクロット・メディカル・インコーポレイテッド 炎症検出用診断剤の製造法
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
ES2126695T3 (es) * 1993-10-22 1999-04-01 Nihon Mediphysics Co Ltd Peptido que tiene afinidad hacia la inflamacion y medio diagnostico radiactivo que lo contiene.
WO1995012414A1 (en) * 1993-11-05 1995-05-11 Repligen Corporation Novel modified pf4 compositions and methods of use

Also Published As

Publication number Publication date
DK0820308T3 (da) 2001-11-12
WO1996032133A2 (de) 1996-10-17
ATE203680T1 (de) 2001-08-15
DE19514088A1 (de) 1996-10-17
EP0820308A2 (de) 1998-01-28
US6706713B1 (en) 2004-03-16
EP0820308B1 (de) 2001-08-01
DE59607417D1 (de) 2001-09-06
WO1996032133A3 (de) 1997-02-13
JPH11503433A (ja) 1999-03-26

Similar Documents

Publication Publication Date Title
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
UY23909A1 (es) Procedimiento para la preparacion de 6- derivados sustitutivos del acido micofenolico
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
ES2186769T3 (es) Complejos estables que comprenden lipidos para la administracion de farmacos y procedimientos para su produccion.
PT801564E (pt) Utilizacao de nebivolol como agente anti-aterogernico
SE9704833D0 (sv) New formulation
BR9709845A (pt) Preparação aquosa de insulina formulação farmacêutica parenteral e processo para aumentar a estabilidade química de uma preparação de insulina
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
ES2162040T3 (es) Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios.
DK1343472T3 (da) Thixotropisk næsespray
PT900563E (pt) Producao de formulacoes farmaceuticas para o tratamento de edema e doencas venosas
KR930019224A (ko) 유산 위험 치료제
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
FR2632525B1 (fr) Application therapeutique de la myeloperoxydase humaine
IE870577L (en) Topical amide preparation
HUP9903892A2 (hu) Hidroxámsavszármazékok
ES2060440T3 (es) Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
CO4340732A1 (es) 4-amino-derivados del acido micofenolico 5-substituido
TR200003352T2 (tr) Yeni pentaerythrit türevleri, bunların imalatı ve kullanımları ile bunların sentezi için ara maddeler

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 820308

Country of ref document: ES